The developers of Alzheimer’s drugs have worked hard to make treatment available to patients.
Tag: JP: 4523
Alzheimer’s Blockbuster Is Coming, but Slowly
The developers of Alzheimer’s drugs have worked hard to make treatment available to patients.
Medicare Plans to Cover Alzheimer’s Drugs
Biogen and Eisai’s Leqembi is slated for full approval this summer.
Biogen Boss Turns Corner on Alzheimer’s Miscues
The biotech company needs to embark on a new growth path as former Sanofi CEO Chris…
FDA Rejects Lilly’s Alzheimer’s Drug Candidate, Seeks More Data
Business Health care Health The setback could delay the potential commercial introduction of a drug called…
A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them.
Pharmaceutical companies may try to cap the price hike in future.
FDA Commissioner Denies Wrongdoing in Approval Process for Biogen Alzheimer’s Drug Aduhelm
Robert Calif acknowledged that the agency made mistakes when it failed to properly document interactions with…
New Alzheimer’s Drug Leqembi Will Be Out of Reach for Most Patients
Health Medicare will not pay for a drug under a previously issued rule restricting use of…
New Alzheimer’s Drug Approved by FDA, Promises to Slow Disease
Health Eisai and Biogen’s Leqembi is the first drug to show that reducing a protein linked…
Newest Alzheimer’s Drugs Take Large But Fraught Step Toward Approval
Positive study results for Eisai-Biogen lifted prospects for its drug and one from Eli Lilly —…